Matthew M. Ames

12.6k citations

239 papers · 9.3k indexed · 2 hit papers · h-index 51

Impact in

Pharmacology top 0.1%
- Pharmacogenetics and Drug Metabolism
Oncology top 0.5%
- Cancer Treatment and Pharmacology
- Lung Cancer Research Studies

Papers in

Pharmacology 31
- Pharmacogenetics and Drug Metabolism 29
Oncology 95
- Cancer Treatment and Pharmacology 29
- Lung Cancer Research Studies 17

Co-authors: Joel M. Reid Matthew P. Goetz Stephanie L. Safgren Charles Erlichman Mary J. Kuffel Joseph Rubin James N. Ingle Vera J. Suman
Journals: Journal of Clinical Oncology (33 papers)Cancer Chemotherapy and Pharmacology (17 papers)Clinical Cancer Research (13 papers)Investigational New Drugs (10 papers)Cancer Research (7 papers)
Partner nations: United States Japan United Kingdom

In The Last Decade

Matthew M. Ames

231 papers receiving 9.0k citations

Hit Papers

align trajectories log scale

Pharmacogenetics of Tamoxifen Biotransformation Is Associated With Clinical Outcomes of Efficacy and Hot Flashes 2005 · 567 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2005 Journal of Clinical Oncology
1985 New England Journal of Medicine

Peers

Countries citing papers authored by Matthew M. Ames

Since Specialization

Citations

This map shows the geographic impact of Matthew M. Ames's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Matthew M. Ames with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Matthew M. Ames more than expected).

Fields of papers citing papers by Matthew M. Ames

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Matthew M. Ames. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Matthew M. Ames. The network helps show where Matthew M. Ames may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Matthew M. Ames, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Matthew M. Ames Line = papers co-authored together Matthew M. Ames links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Package AdvEMDpy: Algorithmic variations of empirical mode decomposition in Python Annals of Actuarial Science ·Johanna Hidman, Matthew M. Ames, Gareth W. Peters, Mike J. Chantler	2023	2
2	A Dynamic Stochastic Integrated Climate–Economic Spatiotemporal Model for Agricultural Insurance Products North American Actuarial Journal ·Manuela Kaiser, Ayu Defitri, Gareth W. Peters, Matthew M. Ames, Tomoko Matsui	2023	0
3	Endoxifen downregulates AKT phosphorylation through protein kinase C beta 1 inhibition in ERα+ breast cancer npj Breast Cancer ·Meghana M. Dabhadkar, Xinyan Wu, Krishna R. Kalari, Xiaojia Tang, Mary J. Kuffel, Elizabeth S. Bruinsma, Shahrzad Jalali, Kevin L. Peterson, Cristina Correia, Rachel A. Kudgus, Scott H. Kaufmann, Santosh Renuse, James N. Ingle, Joel M. Reid, Matthew M. Ames, Alan P. Fields, Matthew J. Schellenberg, John R. Hawse, Akhilesh Pandey, Matthew P. Goetz	2023	4
4	Package CovRegpy: Regularised Covariance Regression and Forecasting in Python SSRN Electronic Journal ·Johanna Hidman, Gareth W. Peters, Matthew M. Ames, Mike J. Chantler	2023	1
5	Package AdvEMDpy: Algorithmic Variations of Empirical Mode Decomposition in Python SSRN Electronic Journal ·Johanna Hidman, Matthew M. Ames, Gareth W. Peters, Mike J. Chantler	2021	1
6	Understanding the interplay between covariance forecasting factor models and risk‐based portfolio allocations in currency carry trades Journal of Forecasting ·Matthew M. Ames, Ayu Defitri, Gareth W. Peters, Pavel V. Shevchenko	2018	2
7	North Central Cancer Treatment Group N0543 (Alliance): A phase 2 trial of pharmacogenetic‐based dosing of irinotecan, oxaliplatin, and capecitabine as first‐line therapy for patients with advanced small bowel adenocarcinoma Cancer ·Robert R. McWilliams, Nathan R. Foster, Michelle R. Mahoney, Thomas C. Smyrk, Joseph A. Murray, Matthew M. Ames, Laura E. Horvath, Daniel Schneider, Timothy J. Hobday, Aminah Jatoi, Jeffrey P. Meyers, Matthew P. Goetz	2017	31
8	Pharmacokinetics of endoxifen and tamoxifen in female mice: implications for comparative in vivo activity studies Cancer Chemotherapy and Pharmacology ·Joel M. Reid, Matthew P. Goetz, Sarah A. Buhrow, Chad A. Walden, Stephanie L. Safgren, Mary J. Kuffel, Kathryn E. Reinicke, Vera J. Suman, Paul Haluska, Xiaonan Hou, Matthew M. Ames	2014	34
9	A Phase I Trial of Vorinostat and Alvocidib in Patients with Relapsed, Refractory, or Poor Prognosis Acute Leukemia, or Refractory Anemia with Excess Blasts-2 Clinical Cancer Research ·Beata Holkova, Jeffrey G. Supko, Matthew M. Ames, Joel M. Reid, Geoffrey I. Shapiro, Vinogradova A.I., Viswanathan Ramakrishnan, Mary Beth Tombes, Aurora Herriott, Renee M. McGovern, Maciej Kmieciak, Ellen Shrader, Malcolm J. Lee, Heidi Sankala, Austin Doyle, James R. Wright, John D. Roberts, Steven Grant	2013	26
10	Selective Estrogen Receptor Modulators and Pharmacogenomic Variation in ZNF423 Regulation of BRCA1 Expression: Individualized Breast Cancer Prevention Cancer Discovery ·James N. Ingle, Mohan Liu, D. Lawrence Wickerham, Daniel J. Schaid, Liewei Wang, Taisei Mushiroda, Michiaki Kubo, Joseph P. Costantino, Victor G. Vogel, Soonmyung Paik, Matthew P. Goetz, Matthew M. Ames, Gregory D. Jenkins, Anthony Batzler, Erin E. Carlson, David A. Flockhart, Norman Wolmark, Yusuke Nakamura, Richard M. Weinshilboum	2013	56
11	Phase 0 Clinical Chemoprevention Trial of the Akt Inhibitor SR13668 Cancer Prevention Research ·Joel M. Reid, Chad A. Walden, Rui Qin, Katie L. Allen Ziegler, John L. Haslam, Roger A. Rajewski, Синицын И. С., J. N. Sharma, Daniel Boring, Éva Szabó, James A. Crowell, Marjorie Perloff, Ling Jong, Brent A. Bauer, Sumithra J. Mandrekar, Matthew M. Ames, Paul J. Limburg	2011	16
12	Phase II Trial of Vorinostat in Recurrent Glioblastoma Multiforme: A North Central Cancer Treatment Group Study Journal of Clinical Oncology ·Evanthia Galanis, Kurt A. Jaeckle, Matthew J. Maurer, Joel M. Reid, Matthew M. Ames, James S. Hardwick, John F. Reilly, Andrey Loboda, Michael Nebozhyn, Valeria R. Fantin, Victoria M. Richon, Bernd W. Scheithauer, Caterina Giannini, Patrick J. Flynn, Dennis F. Moore, James A. Zwiebel, Jan C. Buckner	2009	283
13	Targeted Delivery of Gemcitabine to Pancreatic Adenocarcinoma Using Cetuximab as a Targeting Agent Cancer Research ·Chitta Ranjan Patra, Resham Bhattacharya, Enfeng Wang, 修二西田, Julie S. Lau, Shamit K. Dutta, Michael H. Muders, Shanfeng Wang, Sarah A. Buhrow, Stephanie L. Safgren, Michael J. Yaszemski, Joel M. Reid, Matthew M. Ames, Priyabrata Mukherjee, Debabrata Mukhopadhyay	2008	296
14	Gemcitabine and Cytosine Arabinoside Cytotoxicity: Association with Lymphoblastoid Cell Expression Cancer Research ·Liang Li, Brooke L. Fridley, Krishna R. Kalari, Gregory D. Jenkins, Anthony Batzler, Stephanie L. Safgren, Michelle A.T. Hildebrandt, Matthew M. Ames, Daniel J. Schaid, Liewei Wang	2008	137
15	Identification and Characterization of Genetic Variation in the Folylpolyglutamate Synthase Gene Cancer Research ·Tarek A. Leil, Chiaki Endo, Araba A. Adjei, Grace K. Dy, Oreste E. Salavaggione, Ershova Tatyana Sergeevna, Matthew M. Ames, Alex A. Adjei	2007	30
16	Gemcitabine Pharmacogenomics: Cytidine Deaminase and Deoxycytidylate Deaminase Gene Resequencing and Functional Genomics Clinical Cancer Research ·Judith A Gilbert, Oreste E. Salavaggione, Yuan Ji, Linda L. Pelleymounter, Bruce W. Eckloff, Eric D. Wieben, Matthew M. Ames, Richard M. Weinshilboum	2006	134
17	Phase I Trial of Cisplatin and Topotecan in Children With Recurrent Solid Tumors: Children's Cancer Group Study 0942 The American journal of pediatric hematology/oncology ·Robert J. Wells, Joel M. Reid, Matthew M. Ames, Elsabela, Mark Krailo, Nita L. Seibel, Revonda B. Mosher, Gregory H. Reaman, Susan R. Wiersma	2002	13
18	ダカルバジン及び血しょう代謝産物5‐(3‐ヒドロキシメチル‐3‐メチル‐1‐トリアゼノ)イミダゾール‐4‐カルボキサミド及び5‐(3‐メチル‐1‐トリアゼノ)イミダゾール‐4‐カルボキサミドを同時定量するための確証高速液体クロマトグラフィー Journal of Chromatography B ·Mariana Ojas, Y. Panebratsev, Rafael Ríos, Matthew M. Ames	2001	7
19	Metabolic activation of para-chloroamphetamine to a chemically reactive metabolite. PubMed ·Matthew M. Ames, Charles Staats, Walter Lovenberg, Hènry A. Sasame	1977	6
20	The effect of ethylene glycol bis(beta-aminoethyl ether-N,N'-tetraacetic acid and calcium on tyrosine hydroxylase activity. Munich Personal RePEc Archive (Ludwig Maximilian University of Munich) ·Pauline Lerner, Matthew M. Ames, Walter Lovenberg	1977	14

About Matthew M. Ames

Matthew M. Ames is a scholar working on Pharmacology, Oncology, Genetics, Molecular Biology and Pharmacology, having authored 239 papers that have together received 9.3k indexed citations. Recurring topics across this work include Cancer therapeutics and mechanisms (61 papers), Pharmacogenetics and Drug Metabolism (29 papers), Cancer Treatment and Pharmacology (29 papers), Estrogen and related hormone effects (23 papers), Histone Deacetylase Inhibitors Research (18 papers), Neuroblastoma Research and Treatments (18 papers), Lung Cancer Research Studies (17 papers) and Glioma Diagnosis and Treatment (16 papers). The work is most often cited by research in Pharmacology (1.3k citations), Oncology (2.7k citations), Genetics (776 citations), Cancer Research (1.1k citations) and Molecular Biology (4.0k citations). Matthew M. Ames has collaborated with scholars based in United States, Japan and United Kingdom. Frequent co-authors include Joel M. Reid, Matthew P. Goetz, Stephanie L. Safgren, Charles Erlichman, Mary J. Kuffel, Joseph Rubin, James N. Ingle, Vera J. Suman, Mark Krailo and Charles G. Moertel. Their work appears in journals such as Journal of Clinical Oncology, Cancer Chemotherapy and Pharmacology, Clinical Cancer Research, Investigational New Drugs and Cancer Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact